MedTrace Logo

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

NCT02305485 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 560

Last updated 2016-12-08

No results posted yet for this study

Summary

The NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial is a prospective, multi-center, randomized trial. The study compares NeoVas sirolimus-eluting bioresorbable coronary scaffold with XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) to evaluate the safety and efficacy of NeoVas in the treatment of patients with de novo coronary lesion.

Conditions

Interventions

DEVICE

NeoVas BCS

Subjects receiving NeoVas BCS

DEVICE

XIENCE PRIME EECSS

Subjects receiving XIENCE PRIME EECSS

Sponsors & Collaborators

  • Lepu Medical Technology (Beijing) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yaling Han, MD · The general hospital of Shenyang military region

  • Guosheng Fu · Sir Run Run Shaw Hospital

  • Bo Xu · Beijing Fuwai hospital, National center for cardiovascular diseases China

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-12-31
Completion
2020-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02305485 on ClinicalTrials.gov